OPAL
OPAL – The Oxygen-15 PET/MR Cerebral Perfusion Atlas
Brain perfusion imaging on a simultaneous PET/MRI system with oxygen-15 water in healthy controls and Moyamoya patients, shared to develop and test non-invasive perfusion methods. 120 participants with PET CBF maps, ASL, DSC and diffusion MRI around acetazolamide. Non-commercial research use.
Overview
OPAL is a brain perfusion collection from Stanford University, released through the Stanford AIMI data portal on Redivis. Every participant was scanned on a simultaneous PET/MRI system with oxygen-15 labeled water, the reference method for measuring cerebral blood flow, alongside several MRI perfusion techniques. The aim is to give researchers paired PET and MRI perfusion data for building and validating non-invasive methods, for example ASL quantification or PET CBF synthesis from MRI. The data are organised in BIDS.
Composition
Version 1.0 holds 120 participants: 66 healthy controls and 54 Moyamoya patients scanned before surgery. To study repeatability, 35 controls and 35 patients had two pre-acetazolamide ASL and PET acquisitions in the same session, and 22 controls returned for a second session about one week later. Patients had no follow-up because they went on to surgery. Demographic data are part of the release; the public page does not report the sex or age breakdown.
An ISMRM 2025 abstract by the same group describes an earlier state of the dataset with 70 controls and 50 patients.
Acquisition
All scans come from one 3T GE PET/MRI scanner. The release includes high-resolution structural MRI, diffusion weighted imaging, single-delay pseudo-continuous ASL, DSC bolus perfusion and static 2-minute early-frame [15O]H2O PET with derived CBF maps. Every participant received the vasodilator acetazolamide during each session to measure cerebrovascular reactivity: runs 1 and 2 are before the drug and run 3 is after it. Post-acetazolamide DSC is available for 61 controls and 42 patients. Quantitative PET CBF maps calibrated with phase-contrast MRI, which give global brain blood flow, exist for 40 controls and 17 patients.
Known limitations
- Single site, single scanner, and one patient group (Moyamoya disease).
- The page does not name the structural sequences, so the exact structural contrasts are not listed here.
- Access requires a Redivis account, AIMI membership and a Stanford research agreement whose text is visible only after sign-in. AIMI data are offered for non-commercial research; commercial use needs a separate license.
Cohort
Aggregate numbers from the sources below. Bars are relative to the 120 subjects.
Contrast / sequence
Groups can overlap
- Arterial spin labeling 120 100%
- DSC perfusion 103 86%
Methodology in Redivis dataset page of OPAL v1.0 (Stanford AIMI), overview and access panel
Field strength
- 3 T 120 100%
Methodology in Redivis dataset page of OPAL v1.0 (Stanford AIMI), overview and access panel
Condition by contrast / sequence
Reported cross table. A dot marks a cell the source does not give.
| DSC perfusion | |
|---|---|
| Healthy control | 61 |
| Moyamoya disease | 42 |
Methodology in Redivis dataset page of OPAL v1.0 (Stanford AIMI), overview and access panel
PET tracer
- [15O]H2O 120 100%
Dataset abstract in Redivis dataset page of OPAL v1.0 (Stanford AIMI), overview and access panel
Condition
Groups can overlap
- Healthy control 66 55%
- Moyamoya disease 54 45%
Methodology in Redivis dataset page of OPAL v1.0 (Stanford AIMI), overview and access panel
License and access
Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer
Create an account and accept terms online
Sign in to Redivis, join the Stanford AIMI organization and complete the per-dataset Stanford research agreement requirement. Metadata are public; files are visible only after both steps.
Stanford University School of Medicine Dataset Research Use Agreement (AIMI)
Free for personal, non-commercial research only. You may not share the data or the download link, may not create derivative works, and must not try to re-identify patients. Stanford sells a separate commercial license.
The Redivis access panel names the requirement "Stanford_Research_Agreement"; its text is shown only after sign-in and was not read for this entry. Stanford AIMI states that its datasets are free for non-commercial research use under the applicable data use terms and that commercial use needs a separate commercial license.
What you can do
- No
- Not stated
- Not stated
- No
- Not stated
What you can share
- No
- No
- Share trained models Not stated
What you must do
- Yes
- Share alike No
- Yes
- Ethics approval No
- Manuscript review No
- Release code No
- Return results No
- No
Limits
- Yes
- Location limits No
Commercial license: Yes Companies can apply for a one-year license per dataset, reviewed by a Stanford committee. The page lists an annual fee of USD 70,000 per dataset for agreements contracted in FY25. Details
Citation
Stanford AIMI. (2026). OPAL – The Oxygen-15 PET/MR Cerebral Perfusion Atlas (Version 1.0) [Dataset]. Redivis. https://doi.org/10.57761/2g6b-bm61
Sources
Every number on this page comes from one of these documents. Each chart names the table or page it is taken from. The raw numbers are in stats.csv.
- Redivis dataset page of OPAL v1.0 (Stanford AIMI), overview and access panel website
- DataCite record of the OPAL dataset DOI (version 1.0, 2026) website
- Jiang et al. 2025, Developing a Public Dataset for 15O-H2O PET/MRI with ASL Perfusion in Healthy Controls and Moyamoya Patients (ISMRM 2025, abstract 1521) paper
- Stanford AIMI shared datasets page website